DEEP REMISSION PREDICTS LONG-TERM OUTCOMES FOR ADALIMUMAB-TREATED PATIENTS WITH CROHN?S DISEASE: DATA FROM EXTEND

(1) Centre Hospitalier, Universitaire de Lille, Lille, France

(2) University Hospital ofGasthuisberg, Leuven, Belgium

(3) Mayo Clinic, Rochester, MN, United States

(4) Abbott Laboratories, AbbottPark, IL, United States

(5) Abbott GmbH & Co. KG, Ludwigshafen, Germany



This item was part of the Anti-TNF in IBD: Mono versus combo - safety matters session at UEG Week Barcelona 2010

This item can be cited as: Gut 2010; 59 (Suppl III) A80